Abstract

PurposeMedical staging, surgical planning, and therapeutic decisions are significantly different for brain metastases versus gliomas. Machine learning (ML) algorithms have been developed to differentiate these pathologies. We performed a systematic review to characterize ML methods and to evaluate their accuracy.MethodsStudies on the application of machine learning in neuro-oncology were searched in Ovid Embase, Ovid MEDLINE, Cochrane trials (CENTRAL) and Web of science core-collection. A search strategy was designed in compliance with a clinical librarian and confirmed by a second librarian. The search strategy comprised of controlled vocabulary including artificial intelligence, machine learning, deep learning, magnetic resonance imaging, and glioma. The initial search was performed in October 2020 and then updated in February 2021. Candidate articles were screened in Covidence by at least two reviewers each. A bias analysis was conducted in agreement with TRIPOD, a bias assessment tool similar to CLAIM.ResultsTwenty-nine articles were used for data extraction. Four articles specified model development for solitary brain metastases. Classical ML (cML) algorithms represented 85% of models used, while deep learning (DL) accounted for 15%. cML algorithms performed with an average accuracy, sensitivity, and specificity of 82%, 78%, 88%, respectively; DL performed 84%, 79%, 81%. The support vector machine (SVM) algorithm was the most common used cML model in the literature and convolutional neural networks (CNN) were standard for DL models. We also found T1, T1 post-gadolinium and T2 sequences were most commonly used for feature extraction. Preliminary TRIPOD analysis yielded an average score of 14.25 (range 8–18).ConclusionML algorithms that can accurately classify glioma from brain metastases have been developed. SVM and CNN are leading approaches with high accuracy. Standardized algorithm performance reporting is a clear limitation to be addressed in future studies.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call